Richard Lin founded Acuta Capital Partners in October 2011 and passed away suddenly in August 2018 from an unusually aggressive form of gastroesophageal cancer. Starting with less than $4 million of capital from himself and a handful of friends, Rich grew Acuta’s assets under management to over $600 million prior to his passing. During his seven years leading Acuta, his investment style was characterized by a dedication to “intellectual honesty” with a long-term focus, driven by his venture capital background and an unrelenting search for transformative companies that could alter the standard of care.

Prior to founding Acuta, Rich had spent over 13 years as a healthcare-focused venture capitalist, including as a partner at Three Arch Partners, LP. While at Three Arch, Rich was an investor/board member of many healthcare companies in the therapeutics, medical device, healthcare services and healthcare IT sectors, including Calibra (acquired by J&J), Cameron (Boston Scientific), Confluent (Tyco), ePocrates (Athena Health), inGenuity (Qiagen), Inova (ResMed), Novacept (Cytyc), Salveo (Catamaran), Spiration (Olympus), Sirtris (GSK), Visiogen (Abbott), and Vivant (Tyco). Rich was also a board member and seed investor in Calistoga (acquired by Gilead), which developed a Pi3k inhibitor that is now approved to treat NHL, CLL and Follicular Lymphoma. He also was one of the seed investors in Acerta Pharma B.V. (acquired by Astra Zeneca), which developed a BTK inhibitor that is now approved to treat Mantle Cell Lymphoma.

An avid golfer and beach tennis player, competitive chess player, wine connoisseur, World Series of Poker player and world traveler, Rich held an M.D. from Harvard Medical School where he graduated cum laude and was also named a Howard Hughes Scholar for his research efforts at the National Institutes of Health. He received an M.B.A. from the Stanford Graduate School of Business, where he was an Arjay Miller Scholar, and a B.S., with honors and Phi Beta Kappa, from Stanford University. Rich also spent time as a resident in surgery at the University of California, San Francisco, a member of the Therapeutic Advisory Council for Harvard Medical School, and on faculty at the Stanford Graduate School of Business.

Rich laid the foundation and template for Acuta’s success, and his Acuta family continues to execute and evolve his vision and strategy in his honor and loving memory.

Source from

Posted on 01/04/2021